REG - Ovoca Bio PLC - Notice of AGM

Ovoca BioAnnouncement

07/11/2023 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231107:nRSG6350Sa&default-theme=true

RNS Number : 6350S  Ovoca Bio PLC  07 November 2023

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

 

Notice of AGM

 

Dublin, Ireland, November 7, 2023 - Ovoca Bio, a biopharmaceutical company
with a focus on women's health, announces that a Notice of Annual General
Meeting ("AGM"), containing details of the resolutions to be proposed at the
AGM, has been published and posted to shareholders. The Notice of AGM is also
available on the Company's website at https://ovocabio.com/agm-registration/
(https://ovocabio.com/agm-registration/) .

 

The Company's 2023 AGM will be held via live conference facility on 30
November 2023 at 4 p.m. Further details in relation to shareholder
participation in the meeting is detailed in the Notice of AGM.

 

It will be possible to fully participate in the meeting using the live
conferencing facility provided by the Company for this purpose. Shareholders
will be able to use this facility to vote and /or ask questions. Shareholders
will also be able to submit questions in advance of the AGM in writing by
email to the Company Secretary at info@ovocabio.com to be received no later
than 4 p.m. on 28 November 2023. All correspondence should include sufficient
information to identify the shareholder on the Register of Members. Questions
submitted using these methods will be addressed by the Chairman at the AGM,
where possible.

 

 

End

 

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

 

 

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on
women's health. The Company is currently developing Orenetide (BP-101), a
novel synthetic peptide administered through a nasal spray as a novel
treatment for women with hypoactive sexual desire disorder (HSDD), a condition
characterized by a distressing lack or loss of sexual desire affecting an
estimated ~4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAGIBDBRUGDGXR